1. Home
  2. |Insights
  3. |Cybersecurity Maturity Model Matures: DoD Adds New Requirements to Draft Cybersecurity Certification

Cybersecurity Maturity Model Matures: DoD Adds New Requirements to Draft Cybersecurity Certification

Client Alert | 1 min read | 09.10.19

The Defense Department has released Revision 0.4 of its Cybersecurity Maturity Model Certification (CMMC) that, starting next year, independent auditors are to use to certify contractor compliance with DoD cybersecurity requirements.  Revision 0.4 more than doubles the number of cybersecurity controls across the CMMC’s five maturity “Levels.”  But the DoD emphasizes that it will further down-select these controls and that mature contractor processes may counteract gaps in the final controls’ implementation.  In addition to NIST SP 800-171 (the default standard under DFARS 252.204-7012), Revision 0.4 now incorporates requirements from the NIST Cybersecurity Framework, ISO 27001, and CIS Critical Security Controls, as well as from “additional DIB inputs.”  Notably missing is NIST SP 800-171B, which remains under review.

The DoD is requesting feedback on Revision 0.4 through September 25, 2019, and plans on releasing Revision 0.6 for comment in November 2019.   The final CMMC is expected in January 2020. 

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...